NASDAQ · LQDA
Healthcare · Biotechnology
$45.06
Up+$0.07 (+0.16%)
Updated Nov 2, 2026, 6:22 AM
SID Score
6.3/10
Composite research score
Smart Money
58/100
Neutral
Price performance · LQDA
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
LQDA closed at $45.06 after 20 trading sessions, up 63.02% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $44.555 | $46.29 | $44.24 | $45.06 | 2.09M |
| Oct 29, 2026 | $46.23 | $47.20 | $44.41 | $44.99 | 2.64M |
| Oct 28, 2026 | $45.425 | $47.18 | $45.0001 | $45.72 | 2.27M |
| Oct 27, 2026 | $43.88 | $46.36 | $43.695 | $45.44 | 3.18M |
| Oct 26, 2026 | $42.77 | $45.72 | $42.1201 | $43.74 | 4.12M |
| Oct 23, 2026 | $39.86 | $42.83 | $38.69 | $42.65 | 3.81M |
| Oct 22, 2026 | $38.75 | $40.08 | $38.215 | $39.69 | 3.53M |
| Oct 21, 2026 | $36.65 | $39.20 | $36.51 | $38.86 | 3.88M |
| Oct 20, 2026 | $33.90 | $36.93 | $33.65 | $36.35 | 4M |
| Oct 19, 2026 | $34.42 | $36.82 | $33.755 | $34.13 | 3.03M |
| Oct 16, 2026 | $34.78 | $34.90 | $33.33 | $34.35 | 4.55M |
| Oct 15, 2026 | $34.93 | $35.80 | $32.20 | $34.78 | 7.23M |
| Oct 14, 2026 | $35.70 | $38.64 | $33.12 | $33.94 | 21.14M |
| Oct 13, 2026 | $27.04 | $27.40 | $26.13 | $26.81 | 7.65M |
| Oct 12, 2026 | $29.27 | $30.86 | $27.275 | $27.67 | 4.41M |
| Oct 9, 2026 | $27.06 | $28.53 | $26.665 | $27.38 | 3.62M |
| Oct 8, 2026 | $26.34 | $29.35 | $26.34 | $28.02 | 5.26M |
| Oct 7, 2026 | $25.55 | $27.33 | $24.59 | $26.68 | 6.99M |
| Oct 6, 2026 | $27.95 | $28.30 | $25.76 | $25.91 | 5.31M |
| Oct 5, 2026 | $28.07 | $28.48 | $25.92 | $27.64 | 7.76M |
The latest Smart Investors Daily articles mentioning LQDA.
Company
Market Activity
Research & News
LQDA research
Company profile and research snapshot.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 15, 2026 | HC Wainwright & Co. | Buy | — |
| Oct 14, 2026 | Wells Fargo | Equal-Weight | — |
| Oct 14, 2026 | BTIG | Buy | — |
| Oct 14, 2026 | Needham | Buy | — |
| Oct 14, 2026 | LifeSci Capital | Outperform | — |
No generated briefing is available yet.
Yahoo · Oct 26, 2026
Liquidia Corporation (LQDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Yahoo · Oct 22, 2026
United Therapeutics (UTHR) faces limited near-term upside for Tyvaso following the Liquidia (LQDA) s
Yahoo · Oct 16, 2026
Growth prospects, business challenges, legal changes, and rising competition from SpaceX shaped Wall Street activity this week.
Yahoo · Oct 16, 2026
Liquidia recently reached a global settlement with United Therapeutics, resolving six lawsuits and allowing its YUTREPIA therapy for pulmonary arterial hypertension to remain on the market while agreeing to remove the pulmonary hypertension due to interstitial lung disease indication from the label and not pursue further appeals. The settlement, which involves net payments of about US$380.70 million through 2027, replaces prolonged legal uncertainty with clearer commercial visibility for...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning LQDA.
